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ABSTRACT
Introduction: Toxoplasmosis is usually a benign infection, except in the event of ocular, 
central nervous system (CNS), or congenital disease and particularly when the patient is 
immunocompromised. Treatment consists of drugs that frequently cause adverse effects; 
thus, newer, more effective drugs are needed. In this study, the possible activity of artesunate, 
a drug successfully being used for the treatment of malaria, on Toxoplasma gondii growth in 
cell culture is evaluated and compared with the action of drugs that are already being used 
against this parasite. Methods: LLC-MK2 cells were cultivated in RPMI medium, kept 
in disposable plastic bottles, and incubated at 36ºC with 5% CO2. Tachyzoites of the RH 
strain were used. The following drugs were tested: artesunate, cotrimoxazole, pentamidine, 
pyrimethamine, quinine, and trimethoprim. The effects of these drugs on tachyzoites and 
LLC-MK2 cells were analyzed using nonlinear regression analysis with Prism 3.0 software. 
Results: Artesunate showed a mean tachyzoite inhibitory concentration (IC50) of 0.075µM 
and an LLC MK2 toxicity of 2.003µM. Pyrimethamine was effective at an IC50 of 0.482µM 
and a toxicity of 11.178µM. Trimethoprim alone was effective against the in vitro parasite. 
Cotrimoxazole also was effective against the parasite but at higher concentrations than those 
observed for artesunate and pyrimethamine. Pentamidine and quinine had no inhibitory effect 
over tachyzoites. Conclusions: Artesunate is proven in vitro to be a useful alternative for the 
treatment of toxoplasmosis, implying a subsequent in vivo effect and suggesting the mechanism 
of this drug against the parasite.
Keywords: Artesunate. Treatment. Anti-Toxoplasma activity. Toxicity.
RESUMO
Introdução: Toxoplasmose é geralmente uma infecção benigna, exceto nos eventos de 
doença ocular, congênito e do sistema nervoso central, e particularmente quando o paciente 
é imunocomprometido. O tratamento consiste de drogas que frequentemente causam efeitos 
adversos, então novas drogas, mais efetivas são necessárias. Neste estudo, a possível atividade 
de artesunato, uma droga usada com sucesso no tratamento da malária, sobre o crescimento 
de Toxoplasma gondii em cultura celular é avaliado e comparado à ação de drogas que já 
estão sendo utilizadas contra este parasita. Métodos: Células LLC-MK2 foram cultivadas 
em meio RPMI, mantidas em garrafas plásticas descartáveis e incubados a 36ºC com 5% 
CO2. Taquizoítos da cepa RH foram usados. As seguintes drogas foram testadas: artesunato, 
cotrimoxazol, pentamidina, pirimetamina, quinino e trimetoprima. Os efeitos dessas drogas 
sobre taquizoítos foram analisados por análise regressiva não linear com o software Prism 3.0. 
Resultados: Artesunato mostrou uma concentração inibitória media (IC50) de 0,075µM e 
uma toxicidade sobre células LLC MK2 de 2,003µM. Pirimetamina foi efetiva a uma IC50 de 
0,482µM e uma toxicidade de 11,178µM. Trimetoprima sozinha foi efetiva contra o parasita 
in vitro. Cotrimoxazol também foi efetivo contra o parasita, mas a concentrações mais altas 
que aquelas observadas para artesunato e pirimetamina. Pentamidina e quinino não tiveram 
efeitos inibitórios sobre os taquizoítos. Conclusões: Provou-se que artesunato in vitro pode 
ser uma alternativa útil para o tratamento da toxoplasmose, implicando um subsequente efeito 
in vivo e sugerindo o mecanismo desta droga contra o parasita.
Palavras-chaves: Artesunato. Tratamento. Atividade anti-Toxoplasma. Toxicidade.
Toxoplasmosis is a highly prevalent cosmopolitan 
infection, but the disease occurs in only a fraction 
of infected people, mainly as a nonspecific immune 
activation syndrome, chronically in ocular forms as 
chorioretinitis. The main problems are congenital disease 
and the infection of immunocompromised people, 
especially those with acquired immunodeficiency 
syndrome (AIDS) or those undergoing chemotherapy 
for cancer or transplant rejection1.
The etiological agent of toxoplasmosis is 
Toxoplasma gondii, the development of which has 
many forms. Tachyzoites are found in the acute 
phase of the disease and are responsible for clinical 
manifestations. They are susceptible to the immune 
response of the host and to drug action. Cysts are the 
resistant form of the parasite, persisting for the host’s 
entire life. Cyst walls are resistant to both drugs and 
the immune system2.
Felids are the definitive hosts for the parasite, with 
other mammalians and birds acting as intermediate 
hosts. Humans can be infected either congenitally 
or through ingestion of raw or undercooked meat; 
manipulation of infected meat containing tissue 
cysts; or consumption of water, fresh vegetables, 
or other food contaminated by oocysts eliminated 
in cat feces1,2.
The most effective treatment against toxoplasmosis 
is a combination of the drugs sulfadiazine and 
pyrimethamine, which can cause hematological effects 
that are controlled with the administration of folinic 
acid. An association of great interest is the one between 
trimethoprim and sulfamethoxazole. Known as 
cotrimoxazole, its active compounds act synergistically, 
inhibiting two consecutive steps of folinic acid 
biosynthesis in a manner similar to that observed for 
pyrimethamine-sulfadoxine. Cotrimoxazole is well 
tolerated and less toxic to hematopoiesis. Human 
immunodeficiency virus–acquired immunodeficiency 
syndrome (HIV-AIDS) patients taking cotrimoxazole 
show a high incidence of adverse effects, and its use is 
discouraged in pregnant women because it crosses the 
placental barrier3.
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Although antifolate compounds, such as pyrimethamine, exhibit 
good anti-Toxoplasma activity, their toxicity limits widespread use, 
particularly for extended treatment periods. The discovery of viable 
low-toxicity compounds capable of preventing and treating T. gondii 
would represent a great advance in the treatment of infections 
in immunocompromised patients. Some compounds that are 
effective against species of Plasmodium could be effective against T. 
gondii. Those agents were selected for further testing in the present 
study because malaria and toxoplasmosis are caused by protozoans 
belonging to the phylum Apicomplexa, and antimicrobial agents that 
have been effective for the treatment of malaria, such as artemisinin 
and its derivatives, also have been effective for the treatment of 
toxoplasmosis. Artemisinin (qinghaosu) is a product extracted 
from the plant Artemisia annua L. Despite the fact that artemisinin 
has produced teratogenic effects in laboratory animals, precluding 
its use in pregnant women, few adverse effects have been observed 
in humans4,5.
In the present study, the toxicity of artesunate and its effectiveness 
for the treatment of toxoplasmosis were studied in vitro and compared 
with the actions of three drugs: pyrimethamine, trimethoprim, and 
cotrimoxazole, which are currently in use against toxoplasmosis. 
Pentamidine and quinine, used for the treatment of other protozoans, 
also were evaluated and compared. Pentamidine is an organic 
compound and derivative of guanidine that has shown activity against 
Leishmania sp., African trypanosomiasis, and pneumonia caused by 
Pneumocystis carinii (jiroveci). Quinine is an alkaloid extracted from 
species of the genus Cinchona, the application of which is limited to 
cases of malaria caused by Plasmodium falciparum.
Parasites 
Tachyzoites of the type I RH strain of T. gondii were routinely 
maintained by intraperitoneal passage in BALB/c mice.
Drugs
All drugs were obtained from commercial sources (Sigma, 
USA) or as human use drugs, supplied by the pharmacy of the 
Hospital das Clínicas da Faculdade de Medicina da Universidade de 
São Paulo (HC-FMUSP). Artesunate and quinine dichlorohydrate 
were supplied by Cipla Medpro (Belville, SA), pentamidine was 
supplied by Itaca Labs (Rio de Janeiro, BR), and cotrimoxazole was 
supplied by Ducto (Anapolis, BR).
Cell culture
The epithelial cell line LLC-MK2, derived from rhesus monkey 
(Macaca mulatta) kidneys, was used. Cells were cultivated in RPMI 
medium with the addition of 10% inactivated bovine fetal serum 
and gentamicin. Cultures were kept in disposable plastic bottles and 
incubated at 36ºC with 5% CO2.
In vitro assays of drug effectiveness and toxicity
The assays were conducted in four stages, the first three on 
consecutive days. On the first day, LLC-MK2 cells were extracted 
from a plastic bottle with ATV enzyme and counted in a Neubauer 
counting chamber. Cells were diluted in RPMI medium containing 
10% inactivated bovine fetal serum until a concentration of 1 × 104 
was obtained. One hundred microliters of the mixture was added 
to each well of a 96-well plate and placed inside the CO2 incubator. 
On the second day, the supernatant from all the wells was aspirated. 
Tachyzoites from the peritoneal fluid of BALB/c mice were extracted 
with a syringe and diluted in complete RPMI medium containing 
10% bovine fetal serum until a concentration of 1 × 104 was obtained. 
One hundred microliters of the mixture was added to the wells in 
rows A to E and columns 1 to 12 of the plate and put into a CO2 
incubator. The remaining wells were filled with complete RPMI 
containing 10% bovine fetal serum. On the third day, the plate was 
washed with complete RPMI medium containing 10% inactivated 
bovine fetal serum. A mother solution of each drug was prepared by 
diluting each one in a solution of complete RPMI medium containing 
10% inactivated bovine fetal serum until a 200μL/mL concentration 
was obtained. Two-fold serial dilutions of all compounds were 
performed, starting with initial concentrations of 100μg/mL. 
Therefore, the concentrations used were as follows: 100, 50, 25, 
12.5, 6.25, 3.1, 1.6, 0.8, 0.4, 0.2, and 0.1μg/mL. For pyrimethamine 
and trimethoprim, the first dilution was made in dimethyl sulfoxide, 
and the remaining dilutions were made in RPMI because of the low 
solubility of these compounds in water. On another 96-well plate, 
200μL of each drug solution was pipetted into wells in column 1, 
whereas 100μL of RPMI medium containing 10% inactivated bovine 
fetal serum solution was pipetted into the wells in columns 2 to 12. 
A two-fold serial dilution was performed by transferring 100μL from 
column 1 to those in column 2 and repeating this procedure until 
column 11. The contents of the second plate were transferred to the 
first plate and placed inside the CO2 incubator. The reaction was 
interrupted when the tachyzoites had destroyed all the cells from the 
positive control wells. After that, the supernatant was moved, and the 
plate was washed with PBS, fixed with methanol, and stained with 
1% aqueous crystal violet solution. After being washed, the plate was 
dried, and 200µL of methanol was added to dissolve the stain. The 
A620 was measured with an ELISA microplate reader. Adherent live 
cells were stained. The A620 is proportional to the number of viable 
cells. This allowed both the measurement of T. gondii cell destruction, 
or cell toxicity, and detection of infected or non-infected cell layers. 
Statistical analysis
Drug effects on both tachyzoites in vitro and LLC-MK2 cells 
were analyzed using nonlinear regression analysis with Prism 3.0 
software, yielding mean inhibitory concentrations (IC50) for the 
studied compounds.
Artesunate at a concentration of 100µg/mL killed all cells in 
the culture. Therefore, the experiment was performed again with a 
maximum concentration of 10µg/mL. It was observed that artesunate 
was effective against tachyzoites at an IC50 of 0.075µM, resulting in 
preservation of the cell line (Figure 1A and 1B). The mean toxicity 
of the drug was 2.003µM (Figure 2A and 2B).
Cell death also was observed with pyrimethamine at 100µg/
mL in the cell culture so that experiment also was performed again 
with a maximum concentration of 10µg/mL. It was observed 
that pyrimethamine was effective against tachyzoites at an IC50 of 
0.482µM, resulting in the preservation of the cell line. The mean 
toxicity of the drug was 11.178µM (Figure 3A and 3B).
Cotrimoxazole proved to be effective against tachyzoites at 
an IC50 of 11.884µM, whereas trimethoprim was effective against 
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FIGURE 1 – Morphology of LLC-MK2 cells after (A) Toxoplasma gondii infection and (B) artesunate treatment following parasite challenge. 
Digital images are from inverted microscope phase-contrast microscopy with 20 × objective. 
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FIGURE 2 - A) Artesunate action in cell culture infected with Toxoplasma gondii 
at concentrations of 10 to 0.01µg/mL. B) Artesunate toxicity in cell culture, at 
concentrations of 10 to 0.01µg/mL.
FIGURE 3 - A) Pyrimethamine action in cell culture infected with Toxoplasma 
gondii at concentrations of 10 to 0.01µg/mL. B) Pyrimethamine toxicity in cell 
culture at concentrations of 10 to 0.01µg/mL. 
A
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DISCUSSION
Toxoplasma gondii at an IC50 of 20.116µM. Neither drug was toxic 
to the cell culture at the tested concentrations (Figure 4A and 4B).
Pentamidine had no effect on tachyzoites at the tested 
concentrations, resulting in destruction of the cell line. The same 
results were observed for quinine. The mean toxicity of pentamidine 
was 1,316µM, and for quinine, it was 91.030µM.
The selectivity index (SI) could be calculated only for artesunate 
and pyrimethamine. The SI for the first one was 26.707, and that for 
the latter was 23.191.
In the present study, artesunate showed the highest efficacy, 
followed by pyrimethamine. Moreover, artesunate presented the 
highest toxicity among the studied compounds, again followed by 
pyrimethamine.
An absence of cotrimoxazole and trimethoprim was observed, 
yet each showed a weaker effect than artesunate and pyrimethamine. 
Pentamidine and quinine had no inhibitory effects over T. gondii in 
this study.
The mean inhibitory concentrations and toxicities, 95% 
confidence intervals, and r2 values for all drugs used in the study are 
shown in Table 1. The selectivity index for two of the six drugs could 
be calculated and also is shown. As can be seen, the most effective 
drugs against T. gondii were pyrimethamine and artesunate.
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FIGURE 4 - A) Cotrimoxazole action in cell culture infected with Toxoplasma gondii at concentrations of 100 to 0.1µg/mL. B) Trimethoprim action in cell culture 
infected with Toxoplasma gondii at concentrations of 100 to 0.1µg/mL.
TABLE 1 - Values of inhibitory concentrations and toxic concentrations in LLC-MK2 cells (µg/mL and µM) for the tested drugs and selectivity index.
Drugs IC50 (µM) IC50 (µg/ml) 95% IC (µM) R2 IC50 tox (µM) IC50 tox (µg/ml) 95% IC (µM) R2 SI
Artesunate 0.075 0.029 0.062 to 0.088 0.94 2.003 0.77 1.613 to 2.471 0.97 26.707
Cotrimoxazole 11.884 6.78 12.472 to 13.208 0.99 - >100 - - -
Pentamidine - - - - 1.316 0.76 10.832 to 15.523 0.89 -
Pyrimethamine 0.482 0.12 0.402 to 0.603 0.89 11.178 2.78 5.790 to 21.672 0.91 23.191
Quininum - - - - 91.030 36.12 28.363 to 291.438 0.77 -
Trimethoprim 20.116 5.8 17.842 to 22.354 0.95 - >100 - - -
 IC50: half maximal inhibitory concentration; 95%CI: 95% Confidence interval; IC50 tox: half maximal toxic concentrations; R2: Correlation coefficient  SI: Selectivity index.                               
An in vitro effect of artesunate against T. gondii was found. Previous 
reports had demonstrated that this compound showed action against 
other parasites, such as Plasmodium6 and Fasciola7. Although inhibitory 
concentrations were higher than those used against the parasites that 
cause malaria, artemisinin and many of its derivatives were effective 
against T. gondii5. In this experiment, artesunate exhibited a strong effect 
against T. gondii tachyzoites in in vitro assays. This work represents an 
initial step toward future studies of the in vivo action of this compound 
and its effect on the cystic form of the parasite. Artesunate could be 
an alternative to the standard pyrimethamine-sulfonamide treatment.
Effective action of artesunate against tachyzoites was observed, 
and it was the highest among all studied compounds. Several studies 
demonstrating the action of artemisinin derivatives have been 
conducted, including Ke Ou-Yang et al.8, D’Angelo et al.9, and Sarciron 
et al.10. El Zawary, in 2008, studied the in vitro action of artesunate 
against RH strain Toxoplasma and observed a significant reduction 
in the viability and effect of tachyzoites exposed to drugs compared 
with a no-treatment control. Although the efficacy of artesunate 
was demonstrated both here and in El Zawary, the inhibitory 
concentration values for artesunate found by El Zawary were higher 
than those observed in the present work. However, because there 
is no standard methodology for drug testing in cell lines, different 
outcomes could result11.
Clark et al.12,13 observed that artesunate is toxic to the embryos of 
mice, rabbits, and nonhuman primates, causing cardiovascular and 
skeletal problems, even death, when given at higher doses and over 
longer periods than recommended for the treatment of malaria12,13. 
Gomes TC et al - Artesunate against Toxoplasma gondii
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At this time, no adverse effects related to the drug have been reported 
in pregnant women treated with artemisinin, including artesunate. 
Although the number of pregnant women exposed to artemisinin 
during the first trimester is considered too small to demonstrate 
safety, the absence of any adverse effects to the babies in these limited 
published clinical studies is encouraging. 
In this work, cotrimoxazole was effective against T. gondii and 
not toxic to the cell culture at tested concentrations. The synergistic 
in vitro effect between trimethoprim and sulfamethoxazole was 
demonstrated many decades ago, by Grossman and Remington14 and 
Derouin and Chastang18. More recent studies such as those by Dumas 
et al.15 and Soheilian et al.16 support the use of this combination to 
prevent cerebral and ocular toxoplasmosis14-16.
Lindsay et al.17 examined the ability of pentamidine and nine of 
its analogs to inhibit the replication of RH strain T. gondii in Vero 
cell cultures. In that study, pentamidine at 25 and 10µg/mL was 
shown to have significant effects over tachyzoite replication. Lindsay 
et al.17 obtained a different result from that in the present work, where 
no anti-Toxoplasma activity of pentamidine was observed at tested 
concentrations. The conflicting results between these studies may 
be due to the different cell lines used or differences in methodology 
because there is no standard model among the authors who perform 
assays with drugs17.
Pyrimethamine is the main drug of choice for the treatment of 
toxoplasmosis. It is well known that this drug exhibits in vitro activity 
against the parasite, as demonstrated by studies such as Derouin and 
Chastang18, Cantin and Chamberland19, Ven et al.20, and Meneceur 
et al.4. The findings of the present study were very similar to those 
previously mentioned, all of them showing effective action at 
concentrations between 0.05 and 0.24µg/mL on RH strain. When 
compared with artesunate, pyrimethamine has been shown to be less 
effective but also less toxic. The selectivity index obtained for these 
drugs were similar; therefore, artesunate was shown to be a promising 
option for the treatment of toxoplasmosis18-20.
No anti-Toxoplasma activity was observed for quinine at tested 
concentrations. These results are compatible with the in vitro 
experiments from Holfels, which tested quinine sulfate on RH strain 
T. gondii at 2, 10, and 20µg/mL and observed no inhibitory effects 
on intracellular tachyzoites.
Since the 1970s, several works have demonstrated the 
effectiveness of trimethoprim against T. gondii in vitro, among them, 
Grossman and Remington, Derouin and Chastang, Ven et al.20, and 
D’Angelo et al.9. Most of these works used RH strain, and all of them 
found IC50 values between 2 and 10µg/mL. The authors of these 
studies point out that a murine model is inadequate to evaluate 
trimethoprim’s efficacy because of the difference in the drug’s half-life 
in human and rat sera with a mean toxicity of 60µg/mL, and more 
human in vivo studies are therefore needed. Because of the short half-
life of trimethoprim, a significant inhibitory concentration may not 
be sustained in human sera, which could explain the poor efficacy 
of this agent alone. Therefore, besides its low toxicity, trimethoprim 
on its own is not considered an alternative to pyrimethamine for the 
treatment of toxoplasmosis9,14,18,20.
In this study, artesunate showed the highest efficacy among the 
compounds studied, followed by pyrimethamine. Along with their 
higher efficacy, however, these drugs showed higher toxicity in cell 
culture. Trimethoprim has shown both efficacy and low toxicity, 
but treatment with this drug alone is not effective. It is combined 
with sulfamethoxazole to form cotrimoxazole, which also has been 
tested and shown to be effective and nontoxic at administered 
concentrations, lending support to the use of this drug as an 
alternative treatment to toxoplasmosis.
The data obtained in the present study suggest that artesunate 
could be a useful alternative to antifolates in the treatment of 
toxoplasmosis. Further study of artesunate is still required, 
specifically into its action against T. gondii in vivo and its efficacy 
against tissue cysts. 
The possible toxic effects of artesunate on pregnant women who 
are being treated for malaria should continue to be investigated, 
keeping in mind that the dose necessary to kill T. gondii is higher 
than that for Plasmodium sp.
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